Exploiting the defensive sugars of HIV-1 for drug and vaccine design

Nature

Volumn 446, Issue 7139, 2007, Pages 1038-1045

  Scanlan, Christopher N ^a   Offer, John ^a   Zitzmann, Nicole ^a   Dwek, Raymond A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; CD22 ANTIGEN; CHAPERONE; CHEMOKINE RECEPTOR CCR5; ENVELOPE PROTEIN; EPITOPE; GLUCOSIDASE; GLYCAN DERIVATIVE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G1 2G12 ANTIBODY VACCINE; MIGLUSTAT; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY; ANTIGEN; CARBOHYDRATE; DRUG DEVELOPMENT; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; SUGAR; VACCINE;

B LYMPHOCYTE; BINDING AFFINITY; CARBOHYDRATE ANALYSIS; CD4+ T LYMPHOCYTE; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; GENOME ANALYSIS; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE SUBPOPULATION; VIRION; VIRUS ENVELOPE; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34247636624     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05818     Document Type: Review

References (100)

1. Clark, G. F. et al. Viewing AIDS from a glycobiological perspective: potential linkages to the human fetoembryonic defence system hypothesis. Mol. Hum. Reprod. 3, 5-13 (1997).
2. Ben-Dor, S., Esterman, N., Rubin, E. & Sharon, N. Biases and complex patterns in the residues flanking protein N-glycosylation sites. Glycobiology 14, 95-101 (2004).
3. Gupta, R., Birch, H., Rapacki, K., Brunak, S. & Hansen, J. E. O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins. Nucleic Acids Res. 27, 370-372 (1999).
4. Zhang, M. et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14, 1229-1246 (2004).
5. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
6. Crispin, M. D. et al. Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure. FEBS Lett. 566, 270-274 (2004).
7. Janssen, B. J. et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437, 505-511 (2005).
8. Zhu, X., Borchers, C., Bienstock, R. J. & Tomer, K. B. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39, 11194-11204 (2000).
9. Cutalo, J. M., Deterding, L. J. & Tomer, K. B. Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry. J. Am. Soc. Mass Spectrom. 15, 1545-1555 (2004).
10. Kwong, P. D., Wyatt, R., Sattentau, Q. J., Sodroski, J. & Hendrickson, W. A. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 74, 1961-1972 (2000).
11. Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705-711 (1998).
12. Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998).
13. Sanders, R. W. et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76, 7293-7305 (2002).
14. Chen, B. et al. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433, 834-841 (2005).
15. Chen, B. et al. Determining the structure of an unliganded and fully glycosylated SIV gp120 envelope glycoprotein. Structure 13, 197-211 (2005).
16. Woods, R. J., Pathiaseril, A., Wormald, M. R., Edge, C. J. & Dwek, R. A. The high degree of internal flexibility observed for an oligomannose oligosaccharide does not alter the overall topology of the molecule. Eur. J. Biochem. 258, 372-386 (1998).
17. Szakonyi, G. et al. Structure of the Epstein-Barr virus major envelope glycoprotein. Nature Struct. Mol. Biol. 13, 996-1001 (2006).
18. Moore, J. P., Kitchen, S. G., Pugach, P. & Zack, J. A. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 20, 111-126 (2004).
19. Pollakis, G. et al. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol. Chem. 276, 13433-13441 (2001).
20. Haas, K. M. et al. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J. Immunol. 177, 3063-3073 (2006).
21. Mizuochi, T. et al. Diversity of oligosaccharide structures on the envelope glycoprotein gp 120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J. Biol. Chem. 265, 8519-8524 (1990).
22. Spear, G. T., Zariffard, M. R., Xin, J. & Saifuddin, M. Inhibition of DC-SIGN-mediated trans infection of T cells by mannose-binding lectin. Immunology 110, 80-85 (2003).
23. Ying, H. et al. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res. Hum. Retroviruses 20, 327-335 (2004).
24. Feinberg, H., Mitchell, D. A., Drickamer, K. & Weis, W. I. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294, 2163-2166 (2001).
25. Wu, L. & KewalRamani, V. N. Dendritic-cell interactions with HIV: infection and viral dissemination. Nature Rev. Immunol. 6, 859-868 (2006).
26. Granelli-Piperno, A. et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J. Immunol. 175, 4265-4273 (2005).
27. Nobile, C. et al. Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes. J. Virol. 79, 5386-5399 (2005).
28. Turville, S. G. et al. HIV gp120 receptors on human dendritic cells. Blood 98, 2482-2488 (2001).
29. Boggiano, C., Manel, N. & Littman, D. R. Dendritic cell-mediated trans-enhancement of HIV-1 infectivity is independent of DC-SIGN. J. Virol. 81, 2519-2523 (2007).
30. Varki, A. Nothing in glycobiology makes sense, except in the light of evolution. Cell 126, 841-845 (2006).
31. Gagneux, P. & Varki, A. Evolutionary considerations in relating oligosaccharide diversity to biological function. Glycobiology 9, 747-755 (1999).
32. Blixt, O. et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl Acad. Sci. USA 101, 17033-17038 (2004).
33. Neil, S. J., McKnight, A., Gustafsson, K. & Weiss, R. A. HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation. Blood 105, 4693-4699 (2005).
34. Seymour, R. M., Allan, M. J., Pomiankowski, A. & Gustafsson, K. Evolution of the human ABO polymorphism by two complementary selective pressures. Proc. R. Soc. Lond. B 271, 1065-1072 (2004).
35. Lowe, J. B. & Marth, J. D. A genetic approach to mammalian glycan function. Annu. Rev. Biochem. 72, 643-691 (2003).
36. Reitter, J. N., Means, R. E. & Desrosiers, R. C. A role for carbohydrates in immune evasion in AIDS. Nature Med. 4, 679-684 (1998).
37. Cole, K. S., Steckbeck, J. D., Rowles, J. L., Desrosiers, R. C. & Montelaro, R. C. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J. Virol. 78, 1525-1539 (2004).
38. McCaffrey, R. A., Saunders, C., Hensel, M. & Stamatatos, L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J. Virol. 78, 3279-3295 (2004).
39. Bolmstedt, A. et al. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12, 213-220 (1996).
40. Queitsch, C., Sangster, T. A. & Lindquist, S. Hsp90 as a capacitor of phenotypic variation. Nature 417, 618-624 (2002).
41. True, H. L., Berlin, I. & Lindquist, S. L. Epigenetic regulation of translation reveals hidden genetic variation to produce complex traits. Nature 431, 184-187 (2004).
42. Dacheux, L. et al. Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. J. Virol. 78, 12625-12637 (2004).
43. Sagar, M., Wu, X., Lee, S. & Overbaugh, J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80, 9586-9598 (2006).
44. Derdeyn, C. A. et al. Envelope-constrained neutralization- sensitive HIV-1 after heterosexual transmission. Science 303, 2019-2022 (2004).
45. Li, M. et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80, 11776-11790 (2006).
46. Frost, S. D. et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl Acad. Sci. USA 102, 18514-18519 (2005).
47. Li, B. et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J. Virol. 80, 5211-5218 (2006).
48. Zhang, H. et al. Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology [online] 3, 73 (2006) (doi:10.1186/1742- 4690-3-73).
49. Blay, W. M. et al. Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques. J. Virol. 80, 999-1014 (2006).
50. Fischer, P. B., Karlsson, G. B., Butters, T. D., Dwek, R. A. & Platt, F. M. N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. J. Virol. 70, 7143-7152 (1996).
51. Fischer, P. B. et al. The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J. Virol. 69, 5791-5797 (1995).
52. Zitzmann, N. et al. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl Acad. Sci. USA 96, 11878-11882 (1999).
53. 3. J. Acquir. Immune Defic. Syndr. 7, 139-147 (1994).
54. Tierney, M. et al. The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10, 549-553 (1995).
55. Butters, T. D., Dwek, R. A. & Platt, F. M. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 15, 43R-52R (2005).
56. Ou, W. & Silver, J. Role of protein disulfide isomerase and other thiol-reactive proteins in HIV-1 envelope protein-mediated fusion. Virology 350, 406-417 (2006).
57. Barbouche, R., Miquelis, R., Jones, I. M. & Fenouillet, E. Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion. J. Biol. Chem. 278, 3131-3136 (2003).
58. Helenius, A. & Aebi, M. Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 73, 1019-1049 (2004).
59. Balzarini, J., Van Herrewege, Y., Vermeire, K., Vanham, G. & Schols, D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol. Pharmacol. 71, 3-11 (2007).
60. Esser, M. T. et al. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J. Virol. 73, 4360-4371 (1999).
61. Balzarini, J. Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res. 71, 237-247 (2006).
62. Tsai, C. C. et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retroviruses 20, 11-18 (2004).
63. Chiba, H. et al. Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: isolation, characterization, and biological activities. Biochem. Biophys. Res. Commun. 282, 595-601 (2001).
64. Kutilek, V. D., Sheeter, D. A., Elder, J. H. & Torbett, B. E. Is resistance futile? Curr. Drug Targets Infect. Disord. 3, 295-309 (2003).
65. Balzarini, J. et al. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J. Virol. 80, 8411-8421 (2006).
66. Witvrouw, M. et al. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J. Virol. 79, 7777-7784 (2005).
67. Balzarini, J. Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV. Lancet Infect. Dis. 5, 726-731 (2005).
68. Pantophlet, R. & Burton, D. R. gp120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24, 739-769 (2006).
69. Burton, D. R., Stanfield, R. L. & Wilson, I. A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl Acad. Sci. USA 102, 14943-14948 (2005).
70. Moore, J. P. et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69, 101-109 (1995).
71. Gilbert, P. B. et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191, 666-677 (2005).
72. Zhou, T. et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732-737 (2007).
73. Zolla-Pazner, S. Identifying epitopes of HIV-1 that induce protective antibodies. Nature Rev. Immunol. 4, 199-210 (2004).
74. Stiegler, G. et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17, 1757-1765 (2001).
75. Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100-1108 (1996).
76. Binley, J. M. et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78, 13232-13252 (2004).
77. Saphire, E. O. et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293, 1155-1159 (2001).
78. Ofek, G. et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78, 10724-10737 (2004).
79. Scanlan, C. N. et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120. J. Virol. 76, 7306-7321 (2002).
80. Lee, H. K. et al. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody. Angew. Chem. Int. Ed. Engl. 43, 1000-1003 (2004).
81. Calarese, D. A. et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065-2071 (2003).
82. Dudkin, V. Y. et al. Toward fully synthetic carbohydrate-based HIV antigen design: on the critical role of bivalency. J. Am. Chem. Soc. 126, 9560-9562 (2004).
83. Geng, X., Dudkin, V. Y., Mandal, M. & Danishefsky, S. J. In pursuit of carbohydrate-based HIV vaccines, part 2: the total synthesis of high-mannose-type gp120 fragments - evaluation of strategies directed to maximal convergence. Angew. Chem. Int. Ed. Engl. 43, 2562-2565 (2004).
84. Adams, E. W. et al. Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycan-dependent gp120/protein interactions. Chem. Biol. 11, 875-881 (2004).
85. Wang, L. X., Ni, J., Singh, S. & Li, H. Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design. Chem. Biol. 11, 127-134 (2004).
86. Ni, J., Song, H., Wang, Y., Stamatos, N. M. & Wang, L. X. Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates. Bioconjug. Chem. 17, 493-500 (2006).
87. Wang, L. X. Toward oligosaccharide- and glycopeptide-based HIV vaccines. Curr. Opin. Drug Discov. Devel. 9, 194-206 (2006).
88. Roux, K. H. et al. Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12. Mol. Immunol. 41, 1001-1011 (2004).
89. Freire, T., Bay, S., Vichier-Guerre, S., Lo-Man, R. & Leclerc, C. Carbohydrate antigens: synthesis aspects and immunological applications in cancer. Mini Rev. Med. Chem. 6, 1357-1373 (2006).
90. Kagan, E. et al. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol. Immunother. 54, 424-430 (2005).
91. Riemer, A. B. et al. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur. J. Immunol. 36, 1267-1274 (2006).
92. Pashov, A. et al. Antigenic properties of peptide mimotopes of HIV-1-associated carbohydrate antigens. J. Biol. Chem. 280, 28959-28965 (2005).
93. Slovin, S. F. et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with α-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J. Clin. Oncol. 21, 4292-4298 (2003).
94. Vliegenthart, J. F. Carbohydrate based vaccines. FEBS Lett. 580, 2945-2950 (2006).
95. Komagamine, T. & Yuki, N. Ganglioside mimicry as a cause of Guillain-Barré syndrome. CNS Neurol. Disord. Drug Targets 5, 391-400 (2006).
96. Gemmill, T. R. & Trimble, R. B. Overview of N- and O-linked oligosaccharide structures found in various yeast species. Biochim. Biophys. Acta 1426, 227-237 (1999).
97. Kwong, P. D. et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8, 1329-1339 (2000).
98. Pantophlet, R. et al. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77, 642-658 (2003).
99. Calarese, D. A. et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl Acad. Sci. USA 102, 13372-13377 (2005).
100. Willison, H. J. The immunobiology of Guillain-Barré syndromes. J. Peripher. Nerv. Syst. 10, 94-112 (2005).